|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2017), EMA (2018)) |
IUPAC Name ![]() |
N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine |
International Nonproprietary Names ![]() |
|
INN number | INN |
10036 | abemaciclib |
Synonyms ![]() |
CS-1230 | HY-16297A | LY 2835219 | LY2835219 | Verzenio® | Verzenios® |
Comments |
Abemaciclib (LY2835219) is a selective ATP-competitive inhibitor of the cyclin-dependent kinases CDK4 and CDK6 [6]. |
Database Links ![]() |
|
CAS Registry No. | 1231929-97-7 (source: Scifinder) |
ChEMBL Ligand | CHEMBL3301610 |
GtoPdb PubChem SID | 178103954 |
PubChem CID | 46220502 |
RCSB PDB Ligand | 6ZV |
Search Google for chemical match using the InChIKey | UZWDCWONPYILKI-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | UZWDCWONPYILKI |
Search PubMed clinical trials | abemaciclib |
Search PubMed titles | abemaciclib |
Search PubMed titles/abstracts | abemaciclib |
Search UniChem for chemical match using the InChIKey | UZWDCWONPYILKI-UHFFFAOYSA-N |
Search UniChem for chemicals with the same backbone | UZWDCWONPYILKI |